Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.

Adult Busulfan / therapeutic use Graft vs Host Disease / epidemiology Humans Leukemia, Myeloid, Acute / drug therapy Middle Aged Myelodysplastic Syndromes / therapy Neoplasm Recurrence, Local / drug therapy Propensity Score Retrospective Studies Vidarabine / analogs & derivatives
Allogeneic hematopoietic stem cell transplantation Busulfan Fludarabine Myelodysplastic syndrome

Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
06 2022
Historique:
received: 26 12 2021
revised: 13 02 2022
accepted: 10 03 2022
pubmed: 18 3 2022
medline: 15 6 2022
entrez: 17 3 2022
Statut: ppublish

Résumé

There are limited data comparing myeloablative conditioning with fludarabine/busulfan (Flu/Bu4) and reduced-intensity conditioning with fludarabine/busulfan (Flu/Bu2) in patients with myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed nationwide registry data and compared the outcomes of adult patients with MDS receiving Flu/Bu4 and Flu/Bu2 by propensity score (PS) matching. Patients who met the following criteria were eligible for enrollment: (1) age ≥16 years; (2) diagnosis of de novo MDS; (3) first allo-HSCT between 2006 and 2018; (4) related bone marrow transplantation (BMT) or peripheral blood stem cell transplantation from an HLA-matched donor, unrelated BMT from an HLA-matched or HLA-1 allele-mismatched donor, or unrelated cord blood transplantation; and (5) receiving Flu/Bu4 or Flu/Bu2 as a conditioning regimen. Flu/Bu4 comprised intravenous busulfan (total dose, 12.8 mg/kg) combined with fludarabine (total dose, 125-180 mg/m

Identifiants

DOI: 10.1016/j.jtct.2022.03.011 PMID: 35296446
pubmed: 35296446
pii: S2666-6367(22)00159-2
doi: 10.1016/j.jtct.2022.03.011
pii:
doi:

Substances chimiques

Vidarabine FA2DM6879K
Busulfan G1LN9045DK
fludarabine P2K93U8740

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323.e1-323.e9

Informations de copyright

Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Auteurs

Shuhei Kurosawa (S)

Division of Stem Cell and Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: shuhei-kurosawa@g.ecc.u-tokyo.ac.jp.

Yoshimitsu Shimomura (Y)

Department of Hematology, Kobe City Hospital Organization, Kobe City Medical Centre General Hospital, Kobe, Japan; Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan.

Hidehiro Itonaga (H)

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.

Yuho Najima (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

Takeshi Kobayashi (T)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

Yukiyasu Ozawa (Y)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.

Yoshinobu Kanda (Y)

Division of Hematology, Jichi Medical University, Shimotsuke, Japan.

Shinichi Kako (S)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Toshiro Kawakita (T)

Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.

Ken-Ichi Matsuoka (KI)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Yumiko Maruyama (Y)

Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.

Shuichi Ota (S)

Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.

Hideyuki Nakazawa (H)

Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan.

Kazunori Imada (K)

Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.

Takafumi Kimura (T)

Preparation Department, Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.

Junya Kanda (J)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Takahiro Fukuda (T)

Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.

Yoshiko Atsuta (Y)

Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.

Ken Ishiyama (K)

Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Acides du soufre › Acides sulfoniques › Acides alcanesulfoniques › Alcanesulfonates › Méthanesulfonates › Busulfan › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myélodysplasiques › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Score de propension › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Myeloablative Versus Reduced-Intensity...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléoside purique › Vidarabine › Myeloablative Versus Reduced-Intensity...